Women with early HER2-positive breast cancer after administering lapatinib and trastuzumab drug before surgery showed no signs of residual disease and survived longer without the cancer returning, reports a new study.
from Medindia Health News https://ift.tt/3naNjlP
No comments:
Post a Comment